ProCE Banner Activity

HPTN 083: Safety, Efficacy, and Gender-Affirming Hormonal Therapy Interactions With Long-Acting Injectable CAB for HIV PrEP in Transgender Women

Slideset Download
Conference Coverage
Gender-affirming hormonal therapy did not appear to affect cabotegravir concentrations in transgender women in this preliminary analysis from HPTN 083.

Released: August 01, 2022

Expiration: July 31, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner